|View printer-friendly version|
|October 14, 2005 11:47 a.m.|
|Teva Receives Favorable Ruling From Japanese Patent Office Regarding Pravastatin|
Jerusalem, Israel, October 14, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that trial examiners in the Japanese Patent Office have granted judgment in favor of Teva with regard to Sankyo's Patent No. 3463875 in Japan. Following a trial last August, the Patent Office found Sankyo's patent relating to pravastatin free of epipravastatin to be invalid based on prior intellectual property applications filed by Teva in Japan.